Abstract 3955: Tumor macrophage-mediated antibody dependent cell phagocytosis (ADCP) is theprimary mechanism mediating HER2 mAb (Trastuzumab) anti-tumor responses which can be synergistically enhanced by CD47 innate immune checkpoint blockade
Publication
, Conference
Tsao, L-C; Wei, J-P; Lei, G-J; Wang, T; Yang, X-Y; Liu, C-X; Lyerly, HK; Hartman, ZC
Published in: Immunology
July 1, 2019
Duke Scholars
Published In
Immunology
DOI
Publication Date
July 1, 2019
Start / End Page
3955 / 3955
Publisher
American Association for Cancer Research
Conference Name
Proceedings: AACR Annual Meeting 2019; March 29-April 3, 2019; Atlanta, GA
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 3101 Biochemistry and cell biology
- 1112 Oncology and Carcinogenesis
Citation
APA
Chicago
ICMJE
MLA
NLM
Tsao, L.-C., Wei, J.-P., Lei, G.-J., Wang, T., Yang, X.-Y., Liu, C.-X., … Hartman, Z. C. (2019). Abstract 3955: Tumor macrophage-mediated antibody dependent cell phagocytosis (ADCP) is theprimary mechanism mediating HER2 mAb (Trastuzumab) anti-tumor responses which can be synergistically enhanced by CD47 innate immune checkpoint blockade. In Immunology (pp. 3955–3955). American Association for Cancer Research. https://doi.org/10.1158/1538-7445.sabcs18-3955
Tsao, Li-Chung, Jun-Ping Wei, Gang-jun Lei, Tao Wang, Xiao-Yi Yang, Cong-Xiao Liu, H Kim Lyerly, and Zachary C. Hartman. “Abstract 3955: Tumor macrophage-mediated antibody dependent cell phagocytosis (ADCP) is theprimary mechanism mediating HER2 mAb (Trastuzumab) anti-tumor responses which can be synergistically enhanced by CD47 innate immune checkpoint blockade.” In Immunology, 3955–3955. American Association for Cancer Research, 2019. https://doi.org/10.1158/1538-7445.sabcs18-3955.
Tsao L-C, Wei J-P, Lei G-J, Wang T, Yang X-Y, Liu C-X, et al. Abstract 3955: Tumor macrophage-mediated antibody dependent cell phagocytosis (ADCP) is theprimary mechanism mediating HER2 mAb (Trastuzumab) anti-tumor responses which can be synergistically enhanced by CD47 innate immune checkpoint blockade. In: Immunology. American Association for Cancer Research; 2019. p. 3955–3955.
Tsao, Li-Chung, et al. “Abstract 3955: Tumor macrophage-mediated antibody dependent cell phagocytosis (ADCP) is theprimary mechanism mediating HER2 mAb (Trastuzumab) anti-tumor responses which can be synergistically enhanced by CD47 innate immune checkpoint blockade.” Immunology, American Association for Cancer Research, 2019, pp. 3955–3955. Crossref, doi:10.1158/1538-7445.sabcs18-3955.
Tsao L-C, Wei J-P, Lei G-J, Wang T, Yang X-Y, Liu C-X, Lyerly HK, Hartman ZC. Abstract 3955: Tumor macrophage-mediated antibody dependent cell phagocytosis (ADCP) is theprimary mechanism mediating HER2 mAb (Trastuzumab) anti-tumor responses which can be synergistically enhanced by CD47 innate immune checkpoint blockade. Immunology. American Association for Cancer Research; 2019. p. 3955–3955.
Published In
Immunology
DOI
Publication Date
July 1, 2019
Start / End Page
3955 / 3955
Publisher
American Association for Cancer Research
Conference Name
Proceedings: AACR Annual Meeting 2019; March 29-April 3, 2019; Atlanta, GA
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 3101 Biochemistry and cell biology
- 1112 Oncology and Carcinogenesis